| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Menopause | 87 | 2026 | 261 | 8.970 |
Why?
|
| Hot Flashes | 37 | 2026 | 103 | 5.340 |
Why?
|
| Women's Health | 56 | 2025 | 375 | 4.310 |
Why?
|
| Female | 280 | 2026 | 34125 | 2.460 |
Why?
|
| Vasomotor System | 15 | 2025 | 23 | 2.430 |
Why?
|
| Gonadal Steroid Hormones | 7 | 2026 | 35 | 2.340 |
Why?
|
| Menstrual Cycle | 20 | 2026 | 83 | 2.310 |
Why?
|
| Perimenopause | 21 | 2022 | 32 | 2.050 |
Why?
|
| Estradiol | 26 | 2026 | 261 | 2.030 |
Why?
|
| Breast Neoplasms | 25 | 2025 | 1230 | 1.990 |
Why?
|
| Middle Aged | 184 | 2026 | 18266 | 1.980 |
Why?
|
| Humans | 320 | 2026 | 65528 | 1.940 |
Why?
|
| Adult | 163 | 2026 | 17418 | 1.910 |
Why?
|
| Pregnanediol | 12 | 2026 | 12 | 1.900 |
Why?
|
| Diabetes Mellitus, Type 1 | 17 | 2025 | 632 | 1.830 |
Why?
|
| Follicle Stimulating Hormone | 27 | 2026 | 86 | 1.810 |
Why?
|
| Postmenopause | 17 | 2023 | 239 | 1.640 |
Why?
|
| Surveys and Questionnaires | 48 | 2026 | 2783 | 1.540 |
Why?
|
| Body Mass Index | 28 | 2025 | 888 | 1.510 |
Why?
|
| Longitudinal Studies | 61 | 2025 | 1286 | 1.460 |
Why?
|
| Sleep Wake Disorders | 9 | 2024 | 76 | 1.370 |
Why?
|
| Depression | 19 | 2024 | 916 | 1.320 |
Why?
|
| Luteinizing Hormone | 14 | 2026 | 102 | 1.260 |
Why?
|
| Anticoagulants | 13 | 2023 | 519 | 1.230 |
Why?
|
| Risk-Taking | 3 | 2019 | 161 | 1.200 |
Why?
|
| Cardiovascular Diseases | 17 | 2026 | 866 | 1.170 |
Why?
|
| Nurses, Pediatric | 2 | 2018 | 6 | 1.160 |
Why?
|
| Hope | 2 | 2019 | 10 | 1.140 |
Why?
|
| Compassion Fatigue | 2 | 2018 | 14 | 1.140 |
Why?
|
| Reproductive History | 2 | 2019 | 17 | 1.140 |
Why?
|
| Estrogen Replacement Therapy | 7 | 2018 | 81 | 1.130 |
Why?
|
| Obesity | 13 | 2020 | 1268 | 1.110 |
Why?
|
| Sweating | 12 | 2020 | 27 | 1.100 |
Why?
|
| Cross-Sectional Studies | 47 | 2026 | 2699 | 1.060 |
Why?
|
| Quality of Life | 20 | 2025 | 1271 | 1.000 |
Why?
|
| United States | 72 | 2025 | 8130 | 1.000 |
Why?
|
| Pediatric Obesity | 6 | 2026 | 126 | 0.990 |
Why?
|
| Cancer Survivors | 7 | 2025 | 128 | 0.980 |
Why?
|
| Parents | 11 | 2025 | 410 | 0.890 |
Why?
|
| Ultrasonography, Mammary | 4 | 2020 | 19 | 0.860 |
Why?
|
| Male | 91 | 2026 | 31073 | 0.830 |
Why?
|
| Menopause, Premature | 5 | 2019 | 26 | 0.830 |
Why?
|
| Atrial Fibrillation | 10 | 2021 | 872 | 0.820 |
Why?
|
| Premenopause | 15 | 2024 | 61 | 0.820 |
Why?
|
| Sleep | 15 | 2025 | 239 | 0.800 |
Why?
|
| Phytoestrogens | 5 | 2013 | 9 | 0.790 |
Why?
|
| Aged | 69 | 2025 | 14946 | 0.770 |
Why?
|
| Luteal Phase | 3 | 2020 | 28 | 0.760 |
Why?
|
| Mastectomy, Segmental | 3 | 2020 | 48 | 0.760 |
Why?
|
| Mental Health | 6 | 2019 | 378 | 0.750 |
Why?
|
| Dementia | 2 | 2024 | 272 | 0.740 |
Why?
|
| Reproductive Health | 3 | 2017 | 25 | 0.720 |
Why?
|
| Stress, Psychological | 8 | 2025 | 484 | 0.700 |
Why?
|
| Age Factors | 28 | 2021 | 1593 | 0.690 |
Why?
|
| Estrogens | 7 | 2025 | 117 | 0.690 |
Why?
|
| Osteoporosis, Postmenopausal | 2 | 2020 | 48 | 0.690 |
Why?
|
| Prospective Studies | 32 | 2025 | 3355 | 0.680 |
Why?
|
| Young Adult | 29 | 2025 | 4836 | 0.680 |
Why?
|
| Risk Factors | 44 | 2024 | 5442 | 0.670 |
Why?
|
| Pharmacists | 4 | 2023 | 135 | 0.670 |
Why?
|
| Health Promotion | 6 | 2025 | 518 | 0.670 |
Why?
|
| Reproduction | 4 | 2020 | 100 | 0.670 |
Why?
|
| Self Efficacy | 5 | 2019 | 203 | 0.670 |
Why?
|
| Smoking Cessation | 5 | 2019 | 558 | 0.670 |
Why?
|
| Cohort Studies | 32 | 2024 | 2635 | 0.660 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2020 | 2 | 0.650 |
Why?
|
| Obesity, Metabolically Benign | 1 | 2020 | 4 | 0.650 |
Why?
|
| Lipoproteins, HDL | 5 | 2025 | 36 | 0.650 |
Why?
|
| Pilot Projects | 20 | 2025 | 1020 | 0.640 |
Why?
|
| Progesterone | 6 | 2022 | 168 | 0.640 |
Why?
|
| Information Seeking Behavior | 1 | 2020 | 38 | 0.640 |
Why?
|
| Patient Education as Topic | 8 | 2025 | 483 | 0.640 |
Why?
|
| Universities | 2 | 2019 | 170 | 0.630 |
Why?
|
| Patient Compliance | 4 | 2018 | 365 | 0.620 |
Why?
|
| Sleep Deprivation | 4 | 2026 | 17 | 0.610 |
Why?
|
| Isoflavones | 6 | 2015 | 17 | 0.610 |
Why?
|
| Weight Reduction Programs | 3 | 2026 | 63 | 0.610 |
Why?
|
| Body Weight | 7 | 2018 | 381 | 0.610 |
Why?
|
| Starvation | 1 | 2019 | 11 | 0.600 |
Why?
|
| Hormone Replacement Therapy | 5 | 2018 | 30 | 0.600 |
Why?
|
| Self-Assessment | 1 | 2019 | 60 | 0.600 |
Why?
|
| Adolescent | 31 | 2025 | 6383 | 0.600 |
Why?
|
| Diabetes Mellitus | 4 | 2020 | 555 | 0.600 |
Why?
|
| Patient Discharge | 3 | 2020 | 522 | 0.590 |
Why?
|
| Patients | 1 | 2020 | 113 | 0.590 |
Why?
|
| Child | 23 | 2026 | 4678 | 0.590 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 4 | 2022 | 49 | 0.580 |
Why?
|
| Long-Term Care | 8 | 2021 | 179 | 0.580 |
Why?
|
| Cognitive Dysfunction | 2 | 2022 | 351 | 0.570 |
Why?
|
| Longevity | 2 | 2020 | 119 | 0.560 |
Why?
|
| Time Factors | 21 | 2025 | 3789 | 0.550 |
Why?
|
| Activities of Daily Living | 9 | 2021 | 292 | 0.550 |
Why?
|
| Nursing Staff, Hospital | 3 | 2018 | 72 | 0.550 |
Why?
|
| Exercise | 10 | 2025 | 964 | 0.550 |
Why?
|
| Menstruation | 11 | 2015 | 34 | 0.550 |
Why?
|
| Psychometrics | 3 | 2018 | 392 | 0.550 |
Why?
|
| Anti-Mullerian Hormone | 3 | 2023 | 68 | 0.540 |
Why?
|
| Asthma | 5 | 2026 | 472 | 0.540 |
Why?
|
| Marketing | 1 | 2017 | 21 | 0.530 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2017 | 23 | 0.530 |
Why?
|
| Communication | 4 | 2024 | 593 | 0.530 |
Why?
|
| Social Support | 7 | 2025 | 389 | 0.520 |
Why?
|
| Dehydroepiandrosterone Sulfate | 7 | 2018 | 13 | 0.510 |
Why?
|
| Stroke | 11 | 2021 | 1213 | 0.510 |
Why?
|
| Aging | 11 | 2019 | 767 | 0.500 |
Why?
|
| Behavior Therapy | 3 | 2013 | 168 | 0.500 |
Why?
|
| Occupational Health | 1 | 2018 | 197 | 0.500 |
Why?
|
| Burnout, Professional | 1 | 2018 | 142 | 0.480 |
Why?
|
| Follow-Up Studies | 24 | 2025 | 2511 | 0.480 |
Why?
|
| Pre-Eclampsia | 6 | 2013 | 70 | 0.480 |
Why?
|
| Regression Analysis | 7 | 2020 | 500 | 0.480 |
Why?
|
| Health Behavior | 6 | 2025 | 482 | 0.460 |
Why?
|
| Smoking | 15 | 2019 | 866 | 0.460 |
Why?
|
| Health Status | 11 | 2024 | 451 | 0.460 |
Why?
|
| Herbal Medicine | 1 | 2015 | 3 | 0.460 |
Why?
|
| School Health Services | 3 | 2026 | 80 | 0.450 |
Why?
|
| Primary Health Care | 7 | 2025 | 724 | 0.450 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2026 | 41 | 0.450 |
Why?
|
| Withholding Treatment | 1 | 2015 | 39 | 0.450 |
Why?
|
| Pregnancy | 16 | 2025 | 2432 | 0.450 |
Why?
|
| Parity | 5 | 2025 | 71 | 0.440 |
Why?
|
| Students, Medical | 5 | 2021 | 266 | 0.430 |
Why?
|
| Logistic Models | 19 | 2020 | 1282 | 0.430 |
Why?
|
| Aged, 80 and over | 22 | 2024 | 5611 | 0.430 |
Why?
|
| Weight Loss | 3 | 2014 | 279 | 0.430 |
Why?
|
| Complementary Therapies | 1 | 2015 | 63 | 0.430 |
Why?
|
| Caregivers | 8 | 2025 | 291 | 0.430 |
Why?
|
| Frail Elderly | 7 | 2017 | 114 | 0.430 |
Why?
|
| Carotid Intima-Media Thickness | 3 | 2023 | 13 | 0.420 |
Why?
|
| Tamoxifen | 2 | 2015 | 43 | 0.420 |
Why?
|
| Weight Gain | 5 | 2019 | 169 | 0.420 |
Why?
|
| Incidence | 9 | 2020 | 1410 | 0.420 |
Why?
|
| Anovulation | 3 | 2015 | 10 | 0.410 |
Why?
|
| Equol | 1 | 2013 | 5 | 0.410 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2024 | 772 | 0.400 |
Why?
|
| Nurse Administrators | 1 | 2013 | 18 | 0.400 |
Why?
|
| Homes for the Aged | 3 | 2021 | 161 | 0.400 |
Why?
|
| Nursing Homes | 5 | 2021 | 674 | 0.400 |
Why?
|
| Cognition | 4 | 2025 | 501 | 0.400 |
Why?
|
| Blood Glucose Self-Monitoring | 5 | 2022 | 62 | 0.390 |
Why?
|
| Decision Support Techniques | 4 | 2025 | 193 | 0.390 |
Why?
|
| Menarche | 4 | 2020 | 37 | 0.390 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2013 | 66 | 0.390 |
Why?
|
| Educational Status | 8 | 2020 | 279 | 0.390 |
Why?
|
| Models, Organizational | 1 | 2013 | 91 | 0.390 |
Why?
|
| Transportation | 1 | 2013 | 33 | 0.390 |
Why?
|
| Bicycling | 1 | 2013 | 20 | 0.390 |
Why?
|
| Healthcare Disparities | 3 | 2024 | 403 | 0.390 |
Why?
|
| Attitude to Health | 6 | 2020 | 296 | 0.390 |
Why?
|
| Counseling | 6 | 2021 | 378 | 0.390 |
Why?
|
| Self Care | 5 | 2016 | 215 | 0.380 |
Why?
|
| Massachusetts | 18 | 2025 | 2149 | 0.380 |
Why?
|
| Age of Onset | 5 | 2018 | 175 | 0.380 |
Why?
|
| Patient Acceptance of Health Care | 7 | 2025 | 496 | 0.370 |
Why?
|
| Parent-Child Relations | 3 | 2025 | 67 | 0.370 |
Why?
|
| Blood Glucose | 8 | 2025 | 491 | 0.370 |
Why?
|
| Risk Assessment | 14 | 2021 | 2101 | 0.360 |
Why?
|
| Diet | 9 | 2018 | 539 | 0.360 |
Why?
|
| Alzheimer Disease | 4 | 2024 | 770 | 0.360 |
Why?
|
| Population Surveillance | 4 | 2014 | 210 | 0.360 |
Why?
|
| Self-Management | 2 | 2025 | 70 | 0.360 |
Why?
|
| Pregnancy Proteins | 5 | 2013 | 16 | 0.360 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 5 | 2013 | 24 | 0.350 |
Why?
|
| Education, Medical | 3 | 2021 | 185 | 0.350 |
Why?
|
| Vaginal Diseases | 2 | 2023 | 7 | 0.350 |
Why?
|
| Ovariectomy | 4 | 2023 | 104 | 0.350 |
Why?
|
| Ovary | 3 | 2023 | 106 | 0.350 |
Why?
|
| Anxiety | 8 | 2019 | 438 | 0.340 |
Why?
|
| Vaccination | 5 | 2025 | 379 | 0.340 |
Why?
|
| Prevalence | 9 | 2025 | 1441 | 0.340 |
Why?
|
| Life Style | 12 | 2024 | 320 | 0.340 |
Why?
|
| Attitude of Health Personnel | 4 | 2026 | 634 | 0.340 |
Why?
|
| Carotid Artery Diseases | 2 | 2023 | 61 | 0.340 |
Why?
|
| Socioeconomic Factors | 11 | 2025 | 800 | 0.330 |
Why?
|
| Mindfulness | 3 | 2018 | 70 | 0.330 |
Why?
|
| Biomarkers | 15 | 2025 | 1471 | 0.330 |
Why?
|
| Patient Selection | 3 | 2022 | 486 | 0.320 |
Why?
|
| Gonadotropin-Releasing Hormone | 3 | 2016 | 89 | 0.320 |
Why?
|
| Cholesterol, HDL | 4 | 2025 | 72 | 0.320 |
Why?
|
| Sexual Behavior | 3 | 2024 | 193 | 0.310 |
Why?
|
| Early Detection of Cancer | 2 | 2025 | 326 | 0.310 |
Why?
|
| Kyphosis | 1 | 2009 | 6 | 0.310 |
Why?
|
| Decision Making | 2 | 2023 | 420 | 0.310 |
Why?
|
| Yoga | 1 | 2009 | 15 | 0.310 |
Why?
|
| Body Weight Maintenance | 2 | 2021 | 14 | 0.310 |
Why?
|
| Linear Models | 10 | 2024 | 409 | 0.310 |
Why?
|
| Dogs | 3 | 2009 | 340 | 0.300 |
Why?
|
| Mothers | 3 | 2025 | 283 | 0.300 |
Why?
|
| Frailty | 2 | 2022 | 129 | 0.300 |
Why?
|
| Cross-Cultural Comparison | 3 | 2016 | 49 | 0.300 |
Why?
|
| Adaptation, Psychological | 7 | 2018 | 280 | 0.300 |
Why?
|
| Breast Feeding | 2 | 2025 | 162 | 0.300 |
Why?
|
| Focus Groups | 3 | 2024 | 322 | 0.300 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2009 | 40 | 0.300 |
Why?
|
| Residence Characteristics | 5 | 2025 | 233 | 0.300 |
Why?
|
| Treatment Outcome | 18 | 2022 | 5819 | 0.290 |
Why?
|
| Urinary Incontinence | 2 | 2023 | 44 | 0.290 |
Why?
|
| Cardiologists | 2 | 2019 | 28 | 0.290 |
Why?
|
| Health Personnel | 4 | 2026 | 394 | 0.290 |
Why?
|
| Self Report | 8 | 2020 | 393 | 0.290 |
Why?
|
| Reproducibility of Results | 9 | 2018 | 1701 | 0.290 |
Why?
|
| Cultural Characteristics | 3 | 2007 | 38 | 0.290 |
Why?
|
| Overweight | 5 | 2024 | 255 | 0.290 |
Why?
|
| Qualitative Research | 4 | 2025 | 750 | 0.280 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2025 | 182 | 0.280 |
Why?
|
| Statistics as Topic | 2 | 2021 | 148 | 0.280 |
Why?
|
| Students | 4 | 2022 | 226 | 0.280 |
Why?
|
| Calcium | 2 | 2022 | 589 | 0.280 |
Why?
|
| Tobacco Use Disorder | 3 | 2016 | 245 | 0.280 |
Why?
|
| Case-Control Studies | 11 | 2024 | 1157 | 0.280 |
Why?
|
| Estrone | 7 | 2017 | 13 | 0.280 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2021 | 716 | 0.270 |
Why?
|
| Hypothalamus | 1 | 2008 | 134 | 0.270 |
Why?
|
| Clinical Competence | 5 | 2021 | 733 | 0.260 |
Why?
|
| Inappropriate Prescribing | 2 | 2024 | 68 | 0.260 |
Why?
|
| Veterans | 3 | 2020 | 799 | 0.260 |
Why?
|
| Antigens, CD | 3 | 2013 | 351 | 0.250 |
Why?
|
| Dehydroepiandrosterone | 4 | 2013 | 14 | 0.250 |
Why?
|
| Patient Satisfaction | 5 | 2022 | 438 | 0.250 |
Why?
|
| Lipoproteins | 3 | 2022 | 85 | 0.250 |
Why?
|
| Amenorrhea | 5 | 2015 | 6 | 0.250 |
Why?
|
| Bone Density | 4 | 2015 | 143 | 0.250 |
Why?
|
| Vasodilation | 1 | 2006 | 36 | 0.250 |
Why?
|
| Testosterone | 9 | 2018 | 129 | 0.240 |
Why?
|
| Community Health Services | 4 | 1997 | 128 | 0.240 |
Why?
|
| Social Determinants of Health | 2 | 2025 | 148 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2017 | 511 | 0.240 |
Why?
|
| Program Evaluation | 4 | 2016 | 497 | 0.240 |
Why?
|
| Prenatal Care | 2 | 2020 | 178 | 0.240 |
Why?
|
| Metabolic Syndrome | 3 | 2014 | 147 | 0.240 |
Why?
|
| Sexual Partners | 2 | 2024 | 76 | 0.240 |
Why?
|
| Home Nursing | 5 | 2003 | 21 | 0.240 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2026 | 43 | 0.230 |
Why?
|
| Entropy | 1 | 2025 | 24 | 0.230 |
Why?
|
| Receptors, Cell Surface | 3 | 2013 | 431 | 0.230 |
Why?
|
| Geriatric Assessment | 3 | 2021 | 161 | 0.230 |
Why?
|
| Schools, Medical | 3 | 2021 | 151 | 0.230 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 178 | 0.230 |
Why?
|
| Guidelines as Topic | 1 | 2026 | 162 | 0.230 |
Why?
|
| Sexuality | 3 | 2017 | 26 | 0.220 |
Why?
|
| Electronic Health Records | 4 | 2023 | 384 | 0.220 |
Why?
|
| Analysis of Variance | 5 | 2020 | 612 | 0.220 |
Why?
|
| Publishing | 1 | 2026 | 95 | 0.220 |
Why?
|
| Environmental Pollutants | 1 | 2026 | 97 | 0.220 |
Why?
|
| Directive Counseling | 2 | 2016 | 39 | 0.220 |
Why?
|
| Pregnancy Complications | 2 | 2020 | 392 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2024 | 801 | 0.220 |
Why?
|
| Ovulation | 3 | 2020 | 29 | 0.220 |
Why?
|
| Simulation Training | 2 | 2015 | 65 | 0.220 |
Why?
|
| Circadian Rhythm | 3 | 2025 | 390 | 0.220 |
Why?
|
| Oligomenorrhea | 3 | 2014 | 3 | 0.220 |
Why?
|
| Androgens | 5 | 2014 | 66 | 0.220 |
Why?
|
| Odds Ratio | 12 | 2020 | 764 | 0.210 |
Why?
|
| Comorbidity | 5 | 2021 | 1125 | 0.210 |
Why?
|
| Blood Pressure | 6 | 2023 | 526 | 0.210 |
Why?
|
| Pregnancy, High-Risk | 4 | 2013 | 18 | 0.210 |
Why?
|
| Medication Errors | 2 | 2023 | 110 | 0.210 |
Why?
|
| Social Class | 1 | 2025 | 139 | 0.210 |
Why?
|
| Text Messaging | 1 | 2025 | 95 | 0.210 |
Why?
|
| Internet | 2 | 2017 | 466 | 0.210 |
Why?
|
| Pediatrics | 3 | 2024 | 271 | 0.210 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2016 | 160 | 0.210 |
Why?
|
| Neoplasm Staging | 5 | 2020 | 547 | 0.210 |
Why?
|
| HIV Infections | 4 | 2013 | 966 | 0.200 |
Why?
|
| Telephone | 5 | 2024 | 123 | 0.200 |
Why?
|
| Proportional Hazards Models | 10 | 2020 | 742 | 0.200 |
Why?
|
| Schools | 4 | 2025 | 170 | 0.200 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2023 | 30 | 0.200 |
Why?
|
| Periodicals as Topic | 1 | 2026 | 181 | 0.200 |
Why?
|
| Psychomotor Performance | 1 | 2024 | 139 | 0.200 |
Why?
|
| Hyperandrogenism | 2 | 2014 | 3 | 0.200 |
Why?
|
| Air Pollution | 1 | 2023 | 37 | 0.200 |
Why?
|
| Intensive Care Units | 2 | 2023 | 423 | 0.200 |
Why?
|
| Data Interpretation, Statistical | 2 | 2021 | 195 | 0.200 |
Why?
|
| Attention | 1 | 2024 | 151 | 0.190 |
Why?
|
| Australia | 5 | 2022 | 129 | 0.190 |
Why?
|
| Retrospective Studies | 15 | 2022 | 6882 | 0.190 |
Why?
|
| Curriculum | 5 | 2021 | 612 | 0.190 |
Why?
|
| Goals | 1 | 2023 | 95 | 0.190 |
Why?
|
| Carcinoma, Ductal | 1 | 2022 | 3 | 0.190 |
Why?
|
| Chronic Disease | 6 | 2025 | 761 | 0.190 |
Why?
|
| Licensed Practical Nurses | 1 | 2022 | 3 | 0.190 |
Why?
|
| Pharmaceutical Services | 1 | 2023 | 33 | 0.190 |
Why?
|
| Actigraphy | 4 | 2025 | 50 | 0.190 |
Why?
|
| Cryosurgery | 1 | 2022 | 28 | 0.190 |
Why?
|
| Healthy Lifestyle | 2 | 2021 | 28 | 0.190 |
Why?
|
| Air Pollutants | 1 | 2023 | 95 | 0.180 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 142 | 0.180 |
Why?
|
| Physicians, Primary Care | 2 | 2024 | 79 | 0.180 |
Why?
|
| Mental Recall | 1 | 2002 | 95 | 0.180 |
Why?
|
| Hydrocortisone | 1 | 2023 | 194 | 0.180 |
Why?
|
| Influenza Vaccines | 1 | 2023 | 101 | 0.180 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2022 | 53 | 0.180 |
Why?
|
| Drug Utilization | 2 | 2020 | 208 | 0.180 |
Why?
|
| Education, Nursing, Baccalaureate | 1 | 2022 | 47 | 0.180 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2021 | 16 | 0.180 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 70 | 0.180 |
Why?
|
| Hormones | 2 | 2017 | 62 | 0.180 |
Why?
|
| Mastectomy | 2 | 2020 | 56 | 0.170 |
Why?
|
| Anorexia Nervosa | 2 | 2013 | 16 | 0.170 |
Why?
|
| Medication Systems | 1 | 2021 | 17 | 0.170 |
Why?
|
| Meta-Analysis as Topic | 1 | 2021 | 78 | 0.170 |
Why?
|
| Guideline Adherence | 2 | 2026 | 314 | 0.170 |
Why?
|
| Hyperglycemia | 1 | 2022 | 105 | 0.170 |
Why?
|
| Social Behavior | 2 | 2022 | 90 | 0.170 |
Why?
|
| Predictive Value of Tests | 6 | 2018 | 1114 | 0.170 |
Why?
|
| Microbiota | 1 | 2023 | 165 | 0.170 |
Why?
|
| Health Education | 3 | 2018 | 192 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 466 | 0.170 |
Why?
|
| Antiparkinson Agents | 1 | 2021 | 10 | 0.170 |
Why?
|
| Feasibility Studies | 6 | 2021 | 582 | 0.170 |
Why?
|
| Dopamine Antagonists | 1 | 2021 | 16 | 0.170 |
Why?
|
| Irritable Mood | 1 | 2021 | 16 | 0.170 |
Why?
|
| Staphylococcal Infections | 1 | 2022 | 136 | 0.170 |
Why?
|
| Veterans Health | 2 | 2019 | 157 | 0.170 |
Why?
|
| Meditation | 3 | 2013 | 55 | 0.170 |
Why?
|
| Intraoperative Period | 1 | 2020 | 34 | 0.170 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2018 | 39 | 0.160 |
Why?
|
| Research Design | 5 | 2017 | 585 | 0.160 |
Why?
|
| Coronary Vessels | 1 | 2021 | 124 | 0.160 |
Why?
|
| Margins of Excision | 1 | 2020 | 32 | 0.160 |
Why?
|
| Prognosis | 6 | 2025 | 1792 | 0.160 |
Why?
|
| Coronary Disease | 3 | 2011 | 248 | 0.160 |
Why?
|
| Vaccines | 1 | 2021 | 102 | 0.160 |
Why?
|
| Atherosclerosis | 1 | 2021 | 158 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 122 | 0.160 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2020 | 50 | 0.160 |
Why?
|
| Hospitalization | 4 | 2021 | 1393 | 0.150 |
Why?
|
| Medical Order Entry Systems | 1 | 2020 | 42 | 0.150 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 106 | 0.150 |
Why?
|
| Electronic Mail | 1 | 2020 | 47 | 0.150 |
Why?
|
| Mentors | 2 | 2018 | 120 | 0.150 |
Why?
|
| Health Services for the Aged | 3 | 1996 | 49 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 171 | 0.150 |
Why?
|
| Quality Improvement | 3 | 2019 | 470 | 0.150 |
Why?
|
| Reoperation | 1 | 2020 | 298 | 0.150 |
Why?
|
| Waist Circumference | 2 | 2017 | 47 | 0.150 |
Why?
|
| Arousal | 1 | 2019 | 43 | 0.150 |
Why?
|
| Reminder Systems | 1 | 2020 | 75 | 0.150 |
Why?
|
| Breast Diseases | 2 | 2010 | 45 | 0.150 |
Why?
|
| Maternal Age | 2 | 2018 | 33 | 0.150 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 144 | 0.150 |
Why?
|
| Patient Care | 1 | 2019 | 79 | 0.150 |
Why?
|
| Gonadotropins | 1 | 1999 | 14 | 0.150 |
Why?
|
| Energy Intake | 3 | 2015 | 173 | 0.150 |
Why?
|
| Diabetic Angiopathies | 1 | 2018 | 25 | 0.150 |
Why?
|
| Mexican Americans | 1 | 1998 | 14 | 0.150 |
Why?
|
| Ovarian Diseases | 1 | 2018 | 19 | 0.150 |
Why?
|
| Congenital Abnormalities | 1 | 2018 | 25 | 0.150 |
Why?
|
| Menorrhagia | 3 | 2014 | 18 | 0.150 |
Why?
|
| Dyspareunia | 1 | 2018 | 9 | 0.150 |
Why?
|
| Cardiovascular System | 1 | 2019 | 40 | 0.150 |
Why?
|
| Pregnancy in Diabetics | 1 | 2018 | 12 | 0.140 |
Why?
|
| Pediatric Nursing | 1 | 2018 | 12 | 0.140 |
Why?
|
| Accidental Falls | 2 | 2020 | 129 | 0.140 |
Why?
|
| Documentation | 1 | 2020 | 132 | 0.140 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 1576 | 0.140 |
Why?
|
| Preceptorship | 1 | 2018 | 42 | 0.140 |
Why?
|
| Diabetes, Gestational | 1 | 2020 | 143 | 0.140 |
Why?
|
| Lung Neoplasms | 1 | 2025 | 720 | 0.140 |
Why?
|
| Sensitivity and Specificity | 6 | 2013 | 1173 | 0.140 |
Why?
|
| Affect | 4 | 2022 | 128 | 0.140 |
Why?
|
| Impulsive Behavior | 1 | 2018 | 28 | 0.140 |
Why?
|
| Skilled Nursing Facilities | 1 | 2019 | 81 | 0.140 |
Why?
|
| Social Segregation | 1 | 2018 | 10 | 0.140 |
Why?
|
| Multivariate Analysis | 8 | 2018 | 937 | 0.140 |
Why?
|
| Body Composition | 4 | 2008 | 154 | 0.140 |
Why?
|
| Isoprostanes | 2 | 2007 | 2 | 0.140 |
Why?
|
| Perinatal Care | 1 | 2019 | 73 | 0.140 |
Why?
|
| Dog Diseases | 2 | 2009 | 64 | 0.140 |
Why?
|
| Professional Autonomy | 1 | 2017 | 19 | 0.130 |
Why?
|
| Police | 1 | 2018 | 40 | 0.130 |
Why?
|
| Social Participation | 1 | 2017 | 15 | 0.130 |
Why?
|
| Medicare | 2 | 2021 | 616 | 0.130 |
Why?
|
| Databases, Factual | 3 | 2021 | 877 | 0.130 |
Why?
|
| Muscles | 1 | 1998 | 180 | 0.130 |
Why?
|
| Polypharmacy | 3 | 2024 | 66 | 0.130 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2017 | 3 | 0.130 |
Why?
|
| Politics | 1 | 2017 | 37 | 0.130 |
Why?
|
| Patient Participation | 3 | 2025 | 231 | 0.130 |
Why?
|
| Japan | 5 | 2017 | 64 | 0.130 |
Why?
|
| Running | 2 | 2008 | 84 | 0.130 |
Why?
|
| Cough | 2 | 2017 | 184 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 281 | 0.130 |
Why?
|
| Referral and Consultation | 4 | 2024 | 435 | 0.130 |
Why?
|
| Continuity of Patient Care | 2 | 2015 | 177 | 0.130 |
Why?
|
| Alcohol Drinking | 2 | 2017 | 322 | 0.130 |
Why?
|
| Self Concept | 3 | 2019 | 117 | 0.130 |
Why?
|
| Models, Theoretical | 1 | 1998 | 274 | 0.130 |
Why?
|
| New England | 1 | 2017 | 271 | 0.130 |
Why?
|
| Physicians | 1 | 2022 | 488 | 0.130 |
Why?
|
| Hematoma | 2 | 2007 | 82 | 0.120 |
Why?
|
| Ketamine | 1 | 2017 | 39 | 0.120 |
Why?
|
| Workplace | 1 | 2018 | 180 | 0.120 |
Why?
|
| China | 5 | 2017 | 173 | 0.120 |
Why?
|
| Nurse Practitioners | 1 | 2017 | 121 | 0.120 |
Why?
|
| Blood Pressure Determination | 1 | 2016 | 40 | 0.120 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2017 | 90 | 0.120 |
Why?
|
| Analgesics | 1 | 2017 | 103 | 0.120 |
Why?
|
| Racism | 1 | 2018 | 92 | 0.120 |
Why?
|
| Mental Health Services | 1 | 2020 | 308 | 0.120 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2013 | 21 | 0.120 |
Why?
|
| Pain | 3 | 2023 | 403 | 0.120 |
Why?
|
| Hotlines | 1 | 2016 | 21 | 0.120 |
Why?
|
| Feeding Behavior | 2 | 2015 | 265 | 0.120 |
Why?
|
| Filgrastim | 1 | 2015 | 8 | 0.120 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2015 | 6 | 0.120 |
Why?
|
| Migraine Disorders | 1 | 2016 | 45 | 0.120 |
Why?
|
| Grandparents | 1 | 2015 | 7 | 0.120 |
Why?
|
| Violence | 2 | 1998 | 171 | 0.120 |
Why?
|
| Environment | 1 | 2016 | 126 | 0.120 |
Why?
|
| Disease Progression | 2 | 2018 | 1216 | 0.120 |
Why?
|
| Androstenediol | 2 | 2012 | 2 | 0.120 |
Why?
|
| Victoria | 2 | 2013 | 7 | 0.120 |
Why?
|
| Oxidative Stress | 2 | 2007 | 323 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 539 | 0.120 |
Why?
|
| SEER Program | 2 | 2015 | 75 | 0.120 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2013 | 15 | 0.110 |
Why?
|
| Computer-Assisted Instruction | 2 | 2016 | 81 | 0.110 |
Why?
|
| Spirituality | 2 | 2013 | 43 | 0.110 |
Why?
|
| Administration, Inhalation | 2 | 2026 | 160 | 0.110 |
Why?
|
| Hyperhidrosis | 2 | 2020 | 3 | 0.110 |
Why?
|
| Hysterectomy | 3 | 2023 | 71 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 882 | 0.110 |
Why?
|
| Vagina | 2 | 2023 | 89 | 0.110 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2015 | 39 | 0.110 |
Why?
|
| Motor Activity | 2 | 2015 | 346 | 0.110 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2015 | 22 | 0.110 |
Why?
|
| Data Collection | 2 | 2015 | 384 | 0.110 |
Why?
|
| Epidemiologic Methods | 1 | 1995 | 67 | 0.110 |
Why?
|
| Triglycerides | 4 | 2022 | 250 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2015 | 215 | 0.110 |
Why?
|
| Age Distribution | 6 | 2007 | 259 | 0.110 |
Why?
|
| United Kingdom | 3 | 2020 | 85 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2015 | 164 | 0.110 |
Why?
|
| Child, Preschool | 5 | 2025 | 2077 | 0.110 |
Why?
|
| Health Services | 1 | 2015 | 82 | 0.110 |
Why?
|
| Maternal Health Services | 1 | 2015 | 68 | 0.110 |
Why?
|
| Breast | 2 | 2022 | 193 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2022 | 1328 | 0.110 |
Why?
|
| Length of Stay | 2 | 2017 | 831 | 0.110 |
Why?
|
| Apolipoprotein A-I | 2 | 2025 | 23 | 0.110 |
Why?
|
| Diet Records | 1 | 2014 | 34 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2015 | 233 | 0.100 |
Why?
|
| Diet, Diabetic | 1 | 2014 | 13 | 0.100 |
Why?
|
| Placenta Growth Factor | 5 | 2013 | 17 | 0.100 |
Why?
|
| Sepsis | 2 | 2021 | 293 | 0.100 |
Why?
|
| Risk | 4 | 2020 | 381 | 0.100 |
Why?
|
| Pregnancy Outcome | 1 | 2015 | 203 | 0.100 |
Why?
|
| Workload | 2 | 2013 | 127 | 0.100 |
Why?
|
| Epoxide Hydrolases | 1 | 2013 | 6 | 0.100 |
Why?
|
| Hospital Departments | 1 | 2013 | 12 | 0.100 |
Why?
|
| Relaxation Therapy | 2 | 2011 | 25 | 0.100 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2013 | 37 | 0.100 |
Why?
|
| Hospital Bed Capacity | 1 | 2013 | 27 | 0.100 |
Why?
|
| Contraceptives, Oral, Hormonal | 2 | 2017 | 17 | 0.100 |
Why?
|
| Trust | 2 | 2024 | 79 | 0.100 |
Why?
|
| Suburban Health | 1 | 2013 | 2 | 0.100 |
Why?
|
| Eclampsia | 1 | 1993 | 3 | 0.100 |
Why?
|
| Diagnosis-Related Groups | 1 | 2013 | 87 | 0.100 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2015 | 147 | 0.100 |
Why?
|
| Disability Evaluation | 2 | 2017 | 218 | 0.100 |
Why?
|
| Genetic Carrier Screening | 1 | 2013 | 15 | 0.100 |
Why?
|
| Genes, BRCA2 | 1 | 2013 | 11 | 0.100 |
Why?
|
| Fatigue | 2 | 2025 | 115 | 0.100 |
Why?
|
| Genes, BRCA1 | 1 | 2013 | 17 | 0.100 |
Why?
|
| Adolescent Behavior | 2 | 2014 | 195 | 0.100 |
Why?
|
| Inpatients | 1 | 2016 | 311 | 0.100 |
Why?
|
| Cholesterol, LDL | 2 | 2023 | 104 | 0.100 |
Why?
|
| Coumestrol | 4 | 2013 | 4 | 0.100 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 301 | 0.100 |
Why?
|
| Contraceptives, Oral | 2 | 2013 | 23 | 0.100 |
Why?
|
| Medication Adherence | 2 | 2025 | 199 | 0.100 |
Why?
|
| Lignans | 4 | 2013 | 15 | 0.100 |
Why?
|
| Menstruation Disturbances | 1 | 2012 | 18 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2007 | 2247 | 0.090 |
Why?
|
| Benchmarking | 1 | 2013 | 136 | 0.090 |
Why?
|
| Managed Care Programs | 2 | 2003 | 89 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 123 | 0.090 |
Why?
|
| Dietary Fiber | 1 | 2013 | 79 | 0.090 |
Why?
|
| Europe | 3 | 2018 | 201 | 0.090 |
Why?
|
| Paget's Disease, Mammary | 1 | 2011 | 3 | 0.090 |
Why?
|
| Myocardial Infarction | 4 | 2020 | 924 | 0.090 |
Why?
|
| Pregnancy, Multiple | 2 | 2010 | 10 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 471 | 0.090 |
Why?
|
| Adrenal Glands | 1 | 2011 | 34 | 0.090 |
Why?
|
| Angina Pectoris | 3 | 2020 | 38 | 0.090 |
Why?
|
| Fallopian Tubes | 1 | 2011 | 13 | 0.090 |
Why?
|
| Constipation | 1 | 2011 | 15 | 0.090 |
Why?
|
| Adolescent Development | 1 | 2011 | 16 | 0.090 |
Why?
|
| Patient Simulation | 1 | 2012 | 74 | 0.090 |
Why?
|
| Food | 1 | 2012 | 76 | 0.090 |
Why?
|
| Memory | 1 | 2012 | 123 | 0.090 |
Why?
|
| Chi-Square Distribution | 3 | 2018 | 416 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2012 | 145 | 0.090 |
Why?
|
| Bone Remodeling | 1 | 2011 | 25 | 0.090 |
Why?
|
| Consensus | 1 | 2012 | 185 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2013 | 401 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2013 | 239 | 0.080 |
Why?
|
| Religion and Medicine | 1 | 2011 | 19 | 0.080 |
Why?
|
| Hydroxyestrones | 2 | 2007 | 4 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 467 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2023 | 376 | 0.080 |
Why?
|
| Nipples | 1 | 2010 | 14 | 0.080 |
Why?
|
| Preoperative Care | 2 | 2022 | 200 | 0.080 |
Why?
|
| Defibrillators, Implantable | 1 | 2013 | 273 | 0.080 |
Why?
|
| Hemorrhage | 2 | 2022 | 280 | 0.080 |
Why?
|
| Clinical Clerkship | 3 | 2016 | 93 | 0.080 |
Why?
|
| Follicular Phase | 2 | 2008 | 15 | 0.080 |
Why?
|
| Critical Illness | 2 | 2023 | 332 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 738 | 0.080 |
Why?
|
| Myocardial Revascularization | 2 | 2011 | 78 | 0.080 |
Why?
|
| Hypoglycemia | 3 | 2016 | 65 | 0.080 |
Why?
|
| Marital Status | 4 | 2018 | 45 | 0.080 |
Why?
|
| Bipolar Disorder | 1 | 2012 | 249 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2013 | 460 | 0.080 |
Why?
|
| Family | 4 | 1994 | 247 | 0.080 |
Why?
|
| Chemoprevention | 1 | 2009 | 41 | 0.080 |
Why?
|
| Premenstrual Syndrome | 3 | 2018 | 100 | 0.080 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2009 | 3 | 0.080 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 167 | 0.080 |
Why?
|
| Walking | 2 | 2022 | 241 | 0.080 |
Why?
|
| Ambulatory Care | 2 | 2023 | 320 | 0.070 |
Why?
|
| Lipids | 2 | 2009 | 322 | 0.070 |
Why?
|
| Single-Blind Method | 1 | 2009 | 144 | 0.070 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2009 | 35 | 0.070 |
Why?
|
| Posture | 1 | 2009 | 128 | 0.070 |
Why?
|
| Nose Neoplasms | 1 | 2009 | 17 | 0.070 |
Why?
|
| Cat Diseases | 1 | 2009 | 19 | 0.070 |
Why?
|
| Language | 2 | 2023 | 154 | 0.070 |
Why?
|
| Least-Squares Analysis | 2 | 2006 | 24 | 0.070 |
Why?
|
| Phenols | 2 | 2026 | 84 | 0.070 |
Why?
|
| Endoglin | 3 | 2013 | 10 | 0.070 |
Why?
|
| Breeding | 1 | 2008 | 29 | 0.070 |
Why?
|
| Personality | 1 | 2008 | 29 | 0.070 |
Why?
|
| Angiogenic Proteins | 1 | 2008 | 4 | 0.070 |
Why?
|
| Lymphoma | 1 | 2009 | 103 | 0.070 |
Why?
|
| Infant, Newborn | 4 | 2025 | 1451 | 0.070 |
Why?
|
| Sex Hormone-Binding Globulin | 4 | 2012 | 17 | 0.070 |
Why?
|
| Pandemics | 2 | 2025 | 676 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 427 | 0.070 |
Why?
|
| Abdominal Fat | 1 | 2007 | 6 | 0.070 |
Why?
|
| Software Validation | 1 | 2007 | 9 | 0.070 |
Why?
|
| Fractures, Stress | 1 | 2007 | 12 | 0.070 |
Why?
|
| Jogging | 1 | 2007 | 3 | 0.070 |
Why?
|
| Lifting | 1 | 2007 | 6 | 0.070 |
Why?
|
| Observational Studies as Topic | 2 | 2018 | 66 | 0.070 |
Why?
|
| Glucocorticoids | 1 | 2009 | 190 | 0.070 |
Why?
|
| Vegetables | 1 | 2007 | 69 | 0.070 |
Why?
|
| Neuropsychological Tests | 2 | 2025 | 410 | 0.060 |
Why?
|
| Health Status Indicators | 1 | 2007 | 94 | 0.060 |
Why?
|
| Craniocerebral Trauma | 2 | 1998 | 56 | 0.060 |
Why?
|
| Women | 2 | 2012 | 44 | 0.060 |
Why?
|
| Confidence Intervals | 4 | 2013 | 239 | 0.060 |
Why?
|
| Zinc | 1 | 2007 | 95 | 0.060 |
Why?
|
| Brain | 2 | 1993 | 1606 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2006 | 3 | 0.060 |
Why?
|
| Dietary Fats | 1 | 2007 | 178 | 0.060 |
Why?
|
| Life Change Events | 1 | 2007 | 66 | 0.060 |
Why?
|
| Brachial Artery | 1 | 2006 | 28 | 0.060 |
Why?
|
| Blood Flow Velocity | 1 | 2006 | 72 | 0.060 |
Why?
|
| Probability | 2 | 2007 | 170 | 0.060 |
Why?
|
| Cholesterol | 4 | 2013 | 263 | 0.060 |
Why?
|
| Glycemic Index | 1 | 2006 | 23 | 0.060 |
Why?
|
| Computers, Handheld | 1 | 2006 | 37 | 0.060 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2006 | 22 | 0.060 |
Why?
|
| Echocardiography | 2 | 2008 | 512 | 0.060 |
Why?
|
| Employment | 3 | 2003 | 131 | 0.060 |
Why?
|
| Home Care Services | 3 | 2003 | 99 | 0.060 |
Why?
|
| Dietary Carbohydrates | 1 | 2006 | 62 | 0.060 |
Why?
|
| Corpus Luteum | 3 | 2017 | 8 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2019 | 393 | 0.060 |
Why?
|
| Phthalic Acids | 1 | 2026 | 41 | 0.060 |
Why?
|
| Leptin | 1 | 2026 | 89 | 0.060 |
Why?
|
| General Surgery | 1 | 2008 | 215 | 0.060 |
Why?
|
| Aminocaproic Acid | 1 | 2005 | 3 | 0.060 |
Why?
|
| Primary Prevention | 2 | 1997 | 136 | 0.060 |
Why?
|
| Climacteric | 2 | 2003 | 4 | 0.060 |
Why?
|
| Femoral Artery | 1 | 2006 | 103 | 0.060 |
Why?
|
| Aprotinin | 1 | 2005 | 11 | 0.060 |
Why?
|
| Leuprolide | 2 | 2016 | 18 | 0.060 |
Why?
|
| Fluorocarbons | 1 | 2026 | 50 | 0.060 |
Why?
|
| Antifibrinolytic Agents | 1 | 2005 | 19 | 0.060 |
Why?
|
| Quality of Health Care | 3 | 2019 | 531 | 0.060 |
Why?
|
| Hemostatics | 1 | 2005 | 27 | 0.060 |
Why?
|
| Postoperative Hemorrhage | 1 | 2005 | 39 | 0.060 |
Why?
|
| Healthy Volunteers | 2 | 2016 | 73 | 0.060 |
Why?
|
| Suicide, Attempted | 1 | 1986 | 111 | 0.060 |
Why?
|
| Heart Failure | 2 | 2003 | 943 | 0.050 |
Why?
|
| Cholinergic Antagonists | 1 | 2024 | 32 | 0.050 |
Why?
|
| Deprescriptions | 1 | 2024 | 28 | 0.050 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2005 | 74 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 67 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 271 | 0.050 |
Why?
|
| Survival Rate | 4 | 2011 | 862 | 0.050 |
Why?
|
| Mutation | 1 | 2013 | 2679 | 0.050 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2024 | 29 | 0.050 |
Why?
|
| Radiology | 1 | 2008 | 262 | 0.050 |
Why?
|
| Urban Health | 2 | 1994 | 40 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2024 | 38 | 0.050 |
Why?
|
| Reaction Time | 1 | 2024 | 128 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2022 | 749 | 0.050 |
Why?
|
| Potentially Inappropriate Medication List | 1 | 2024 | 15 | 0.050 |
Why?
|
| Apolipoproteins | 1 | 2023 | 14 | 0.050 |
Why?
|
| Combined Modality Therapy | 4 | 2009 | 375 | 0.050 |
Why?
|
| Lipoprotein(a) | 1 | 2003 | 8 | 0.050 |
Why?
|
| Nitrogen Dioxide | 1 | 2023 | 8 | 0.050 |
Why?
|
| California | 2 | 2015 | 177 | 0.050 |
Why?
|
| Polysomnography | 2 | 2014 | 59 | 0.050 |
Why?
|
| Pituitary-Adrenal System | 1 | 2023 | 60 | 0.050 |
Why?
|
| Atrophy | 1 | 2023 | 87 | 0.050 |
Why?
|
| Mentoring | 1 | 2024 | 60 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 694 | 0.050 |
Why?
|
| Saliva | 1 | 2023 | 101 | 0.050 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2023 | 88 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 106 | 0.050 |
Why?
|
| Ovulation Detection | 1 | 2002 | 4 | 0.050 |
Why?
|
| Utilization Review | 1 | 2003 | 32 | 0.050 |
Why?
|
| Apolipoproteins B | 1 | 2022 | 19 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2023 | 66 | 0.050 |
Why?
|
| Drug Utilization Review | 1 | 2003 | 52 | 0.050 |
Why?
|
| Likelihood Functions | 2 | 2002 | 69 | 0.050 |
Why?
|
| Fee-for-Service Plans | 1 | 2003 | 70 | 0.050 |
Why?
|
| Methicillin | 1 | 2022 | 5 | 0.050 |
Why?
|
| Blood Coagulation | 1 | 2022 | 41 | 0.050 |
Why?
|
| Hospitals | 2 | 2022 | 391 | 0.050 |
Why?
|
| Methicillin Resistance | 1 | 2022 | 23 | 0.050 |
Why?
|
| Professional-Family Relations | 1 | 2023 | 92 | 0.050 |
Why?
|
| Orexin Receptor Antagonists | 1 | 2022 | 2 | 0.050 |
Why?
|
| Terminally Ill | 1 | 2002 | 17 | 0.050 |
Why?
|
| Checklist | 1 | 2023 | 73 | 0.050 |
Why?
|
| Lipoproteins, LDL | 1 | 2022 | 49 | 0.050 |
Why?
|
| Azepines | 1 | 2022 | 23 | 0.050 |
Why?
|
| Intention | 1 | 2022 | 72 | 0.050 |
Why?
|
| Antipsychotic Agents | 1 | 2024 | 307 | 0.050 |
Why?
|
| Ankle Brachial Index | 1 | 2021 | 13 | 0.040 |
Why?
|
| Pulse Wave Analysis | 1 | 2021 | 15 | 0.040 |
Why?
|
| Triazoles | 1 | 2022 | 66 | 0.040 |
Why?
|
| Parenting | 2 | 2014 | 76 | 0.040 |
Why?
|
| Sex Factors | 3 | 2011 | 996 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2023 | 222 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2003 | 152 | 0.040 |
Why?
|
| Drug Storage | 1 | 2021 | 23 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2022 | 184 | 0.040 |
Why?
|
| Diuretics | 1 | 2021 | 59 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 166 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2021 | 59 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 143 | 0.040 |
Why?
|
| Personality Inventory | 2 | 2013 | 57 | 0.040 |
Why?
|
| Terminal Care | 1 | 2002 | 118 | 0.040 |
Why?
|
| Pharmacy | 1 | 2021 | 19 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2020 | 67 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2024 | 428 | 0.040 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2000 | 29 | 0.040 |
Why?
|
| Animals | 6 | 2013 | 21529 | 0.040 |
Why?
|
| Phospholipids | 1 | 2020 | 82 | 0.040 |
Why?
|
| Video Recording | 1 | 2021 | 142 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2020 | 12 | 0.040 |
Why?
|
| Electronics | 1 | 2000 | 33 | 0.040 |
Why?
|
| Biopsy | 4 | 2007 | 457 | 0.040 |
Why?
|
| Interpersonal Relations | 4 | 2005 | 158 | 0.040 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2020 | 45 | 0.040 |
Why?
|
| Insulin Resistance | 1 | 2003 | 413 | 0.040 |
Why?
|
| Health Surveys | 3 | 2006 | 318 | 0.040 |
Why?
|
| Sexual Health | 1 | 2019 | 8 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2021 | 311 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2021 | 338 | 0.040 |
Why?
|
| Sleep Arousal Disorders | 1 | 2019 | 1 | 0.040 |
Why?
|
| Mobility Limitation | 1 | 2020 | 49 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 275 | 0.040 |
Why?
|
| Knowledge | 1 | 2019 | 32 | 0.040 |
Why?
|
| Research Report | 1 | 2019 | 26 | 0.040 |
Why?
|
| Insulin | 3 | 2009 | 693 | 0.040 |
Why?
|
| Calcium, Dietary | 2 | 2011 | 29 | 0.040 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 156 | 0.040 |
Why?
|
| Factor Xa Inhibitors | 1 | 2019 | 37 | 0.040 |
Why?
|
| Observation | 1 | 2019 | 30 | 0.040 |
Why?
|
| Cardiology | 1 | 2021 | 170 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 726 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 2 | 2001 | 99 | 0.040 |
Why?
|
| Ovarian Follicle | 1 | 1999 | 39 | 0.040 |
Why?
|
| Coitus | 1 | 2018 | 15 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 49 | 0.040 |
Why?
|
| Causality | 1 | 1998 | 59 | 0.040 |
Why?
|
| Forecasting | 3 | 1994 | 232 | 0.040 |
Why?
|
| Registries | 1 | 2022 | 904 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 293 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2020 | 230 | 0.040 |
Why?
|
| Feedback | 1 | 2018 | 93 | 0.040 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 2 | 2009 | 3 | 0.040 |
Why?
|
| Amnesia | 1 | 1998 | 9 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 167 | 0.030 |
Why?
|
| Estrogen Receptor beta | 2 | 2009 | 24 | 0.030 |
Why?
|
| Cigarette Smoking | 1 | 2018 | 58 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 2 | 2009 | 50 | 0.030 |
Why?
|
| Thinness | 1 | 2018 | 44 | 0.030 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 74 | 0.030 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 1997 | 9 | 0.030 |
Why?
|
| Hospital Restructuring | 1 | 1997 | 1 | 0.030 |
Why?
|
| Heart Rate | 1 | 2019 | 331 | 0.030 |
Why?
|
| Anxiety Disorders | 1 | 2019 | 201 | 0.030 |
Why?
|
| Personnel Turnover | 1 | 1997 | 24 | 0.030 |
Why?
|
| Hallucinations | 1 | 2017 | 18 | 0.030 |
Why?
|
| Lactation | 1 | 2017 | 77 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2013 | 743 | 0.030 |
Why?
|
| C-Reactive Protein | 2 | 2009 | 167 | 0.030 |
Why?
|
| Learning | 1 | 2018 | 185 | 0.030 |
Why?
|
| Fertility Agents, Female | 1 | 2016 | 6 | 0.030 |
Why?
|
| Depressive Disorder | 2 | 2012 | 288 | 0.030 |
Why?
|
| Latin America | 1 | 2016 | 17 | 0.030 |
Why?
|
| Middle East | 1 | 2016 | 13 | 0.030 |
Why?
|
| Adaptation, Physiological | 2 | 2008 | 131 | 0.030 |
Why?
|
| Nurse's Role | 1 | 2017 | 124 | 0.030 |
Why?
|
| Bias | 1 | 1997 | 117 | 0.030 |
Why?
|
| Job Satisfaction | 1 | 1997 | 143 | 0.030 |
Why?
|
| Gonadotropins, Pituitary | 1 | 1996 | 3 | 0.030 |
Why?
|
| Blood Specimen Collection | 1 | 1996 | 20 | 0.030 |
Why?
|
| Periodicity | 1 | 2016 | 49 | 0.030 |
Why?
|
| Adipose Tissue | 2 | 2009 | 301 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2015 | 21 | 0.030 |
Why?
|
| Community-Based Participatory Research | 1 | 2016 | 62 | 0.030 |
Why?
|
| Safety | 1 | 2016 | 148 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2015 | 41 | 0.030 |
Why?
|
| Axilla | 1 | 2015 | 18 | 0.030 |
Why?
|
| Peer Group | 1 | 2016 | 110 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2015 | 41 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 92 | 0.030 |
Why?
|
| Femur Neck | 1 | 2015 | 12 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 57 | 0.030 |
Why?
|
| Michigan | 1 | 2015 | 44 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2015 | 94 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 567 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2015 | 125 | 0.030 |
Why?
|
| Health Services Research | 3 | 2003 | 271 | 0.030 |
Why?
|
| Health | 1 | 1994 | 31 | 0.030 |
Why?
|
| Disease | 1 | 1994 | 27 | 0.030 |
Why?
|
| Endocardium | 1 | 1994 | 14 | 0.030 |
Why?
|
| Health Policy | 2 | 2013 | 198 | 0.030 |
Why?
|
| Galvanic Skin Response | 1 | 2013 | 25 | 0.030 |
Why?
|
| Models, Educational | 1 | 2014 | 67 | 0.030 |
Why?
|
| Psychophysiology | 1 | 2013 | 7 | 0.030 |
Why?
|
| Rhode Island | 1 | 2013 | 104 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 1995 | 223 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2015 | 171 | 0.020 |
Why?
|
| Brain Edema | 1 | 1993 | 31 | 0.020 |
Why?
|
| Comprehensive Health Care | 1 | 2013 | 19 | 0.020 |
Why?
|
| Rhabdomyosarcoma | 1 | 1993 | 16 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1993 | 32 | 0.020 |
Why?
|
| International Cooperation | 1 | 2013 | 91 | 0.020 |
Why?
|
| Androstenedione | 1 | 2012 | 9 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 1993 | 63 | 0.020 |
Why?
|
| Hand | 1 | 1993 | 75 | 0.020 |
Why?
|
| Housing | 1 | 1993 | 75 | 0.020 |
Why?
|
| Perception | 1 | 2013 | 183 | 0.020 |
Why?
|
| Preventive Health Services | 1 | 2013 | 75 | 0.020 |
Why?
|
| Graft Rejection | 1 | 1994 | 302 | 0.020 |
Why?
|
| Observer Variation | 2 | 2007 | 215 | 0.020 |
Why?
|
| Cerebral Hemorrhage | 1 | 1993 | 100 | 0.020 |
Why?
|
| Demography | 2 | 2004 | 180 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 1994 | 179 | 0.020 |
Why?
|
| Body Height | 1 | 2012 | 66 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 231 | 0.020 |
Why?
|
| MEDLINE | 1 | 2012 | 13 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 150 | 0.020 |
Why?
|
| Food Analysis | 1 | 2012 | 31 | 0.020 |
Why?
|
| Myocardium | 1 | 1994 | 298 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 1994 | 534 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 1993 | 271 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 251 | 0.020 |
Why?
|
| Religion and Psychology | 1 | 2011 | 11 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2011 | 43 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 314 | 0.020 |
Why?
|
| Infant | 1 | 2015 | 1718 | 0.020 |
Why?
|
| Ischemic Attack, Transient | 1 | 2011 | 97 | 0.020 |
Why?
|
| Factor VII | 1 | 2009 | 3 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2009 | 15 | 0.020 |
Why?
|
| Genes, Viral | 1 | 1990 | 57 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2009 | 33 | 0.020 |
Why?
|
| Vitamin D | 1 | 2011 | 140 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2009 | 3 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 682 | 0.020 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2009 | 11 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2009 | 13 | 0.020 |
Why?
|
| Aromatase | 1 | 2009 | 15 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2012 | 402 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2009 | 28 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 1995 | 595 | 0.020 |
Why?
|
| Mental Processes | 1 | 2009 | 18 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 1990 | 145 | 0.020 |
Why?
|
| Mammary Glands, Human | 1 | 2009 | 56 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1990 | 120 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 1990 | 95 | 0.020 |
Why?
|
| Cats | 1 | 2009 | 92 | 0.020 |
Why?
|
| Nuclear Family | 1 | 2008 | 18 | 0.020 |
Why?
|
| Temperament | 1 | 2008 | 20 | 0.020 |
Why?
|
| Choristoma | 1 | 1988 | 24 | 0.020 |
Why?
|
| Critical Care | 1 | 2012 | 411 | 0.020 |
Why?
|
| Body Image | 1 | 2008 | 31 | 0.020 |
Why?
|
| Morbidity | 1 | 2008 | 111 | 0.020 |
Why?
|
| Glucuronides | 1 | 2007 | 10 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2008 | 84 | 0.020 |
Why?
|
| Brassica | 1 | 2007 | 7 | 0.020 |
Why?
|
| Heart Atria | 1 | 2008 | 138 | 0.020 |
Why?
|
| Boston | 2 | 2002 | 260 | 0.020 |
Why?
|
| Physical Endurance | 1 | 2007 | 48 | 0.020 |
Why?
|
| Aorta | 1 | 2008 | 114 | 0.020 |
Why?
|
| Gestational Age | 1 | 2008 | 199 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2007 | 76 | 0.020 |
Why?
|
| Pressure | 1 | 2007 | 78 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2007 | 64 | 0.020 |
Why?
|
| Oncology Nursing | 1 | 2007 | 16 | 0.020 |
Why?
|
| Peptides | 1 | 2011 | 603 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 322 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 214 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 1987 | 70 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 1990 | 697 | 0.020 |
Why?
|
| Muscle Stretching Exercises | 1 | 2006 | 4 | 0.020 |
Why?
|
| Mammography | 1 | 2009 | 291 | 0.020 |
Why?
|
| Emotions | 1 | 2009 | 229 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 137 | 0.020 |
Why?
|
| Body Size | 1 | 2006 | 24 | 0.020 |
Why?
|
| Kansas | 1 | 1986 | 3 | 0.020 |
Why?
|
| Medical Records | 1 | 2006 | 140 | 0.020 |
Why?
|
| Psychology, Adolescent | 1 | 1986 | 27 | 0.010 |
Why?
|
| Flavonoids | 1 | 2006 | 75 | 0.010 |
Why?
|
| Anticarcinogenic Agents | 1 | 2006 | 78 | 0.010 |
Why?
|
| P-Selectin | 1 | 2005 | 7 | 0.010 |
Why?
|
| Polyphenols | 1 | 2006 | 61 | 0.010 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2005 | 14 | 0.010 |
Why?
|
| Placebos | 1 | 2005 | 72 | 0.010 |
Why?
|
| Libido | 1 | 2005 | 4 | 0.010 |
Why?
|
| Sickness Impact Profile | 1 | 2005 | 46 | 0.010 |
Why?
|
| CD40 Ligand | 1 | 2005 | 160 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 1988 | 315 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 906 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1993 | 1671 | 0.010 |
Why?
|
| Institutionalization | 2 | 1995 | 23 | 0.010 |
Why?
|
| Body Constitution | 1 | 2004 | 16 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2005 | 106 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 331 | 0.010 |
Why?
|
| Thyrotropin | 1 | 2003 | 35 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2005 | 677 | 0.010 |
Why?
|
| Independent Practice Associations | 1 | 2003 | 2 | 0.010 |
Why?
|
| Time and Motion Studies | 1 | 2003 | 18 | 0.010 |
Why?
|
| Monocytes | 1 | 2005 | 364 | 0.010 |
Why?
|
| Insurance Claim Review | 1 | 2003 | 76 | 0.010 |
Why?
|
| Social Work | 1 | 2003 | 25 | 0.010 |
Why?
|
| Reimbursement, Incentive | 1 | 2003 | 29 | 0.010 |
Why?
|
| Death Certificates | 1 | 2002 | 12 | 0.010 |
Why?
|
| Vulnerable Populations | 1 | 2003 | 92 | 0.010 |
Why?
|
| Psychophysiologic Disorders | 1 | 2001 | 7 | 0.010 |
Why?
|
| Psychology | 1 | 2000 | 45 | 0.010 |
Why?
|
| Paper | 1 | 2000 | 13 | 0.010 |
Why?
|
| Computers | 1 | 2000 | 49 | 0.010 |
Why?
|
| Quality Control | 1 | 2000 | 78 | 0.010 |
Why?
|
| Inflammation | 1 | 2006 | 1186 | 0.010 |
Why?
|
| Accidents | 1 | 1998 | 12 | 0.010 |
Why?
|
| Interview, Psychological | 1 | 1998 | 80 | 0.010 |
Why?
|
| Nursing Administration Research | 1 | 1997 | 7 | 0.010 |
Why?
|
| Cost Control | 1 | 1997 | 24 | 0.010 |
Why?
|
| Population | 1 | 1997 | 14 | 0.010 |
Why?
|
| Algorithms | 1 | 2002 | 1048 | 0.010 |
Why?
|
| Sampling Studies | 1 | 1997 | 67 | 0.010 |
Why?
|
| Organizational Innovation | 1 | 1997 | 83 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1999 | 226 | 0.010 |
Why?
|
| Global Health | 1 | 1997 | 186 | 0.010 |
Why?
|
| Condoms | 1 | 1993 | 47 | 0.010 |
Why?
|
| Physical Examination | 1 | 1994 | 110 | 0.010 |
Why?
|
| Connecticut | 1 | 1993 | 90 | 0.010 |
Why?
|
| Puerto Rico | 1 | 1993 | 141 | 0.010 |
Why?
|
| Social Change | 1 | 1993 | 13 | 0.010 |
Why?
|
| Electrons | 1 | 1993 | 36 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 1993 | 87 | 0.010 |
Why?
|
| Social Environment | 1 | 1993 | 94 | 0.010 |
Why?
|
| Random Allocation | 1 | 1993 | 201 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1994 | 383 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 1993 | 224 | 0.010 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1990 | 7 | 0.000 |
Why?
|
| Restriction Mapping | 1 | 1990 | 51 | 0.000 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 42 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1993 | 558 | 0.000 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1990 | 85 | 0.000 |
Why?
|
| Transfection | 1 | 1990 | 707 | 0.000 |
Why?
|
| Base Sequence | 1 | 1990 | 1346 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1990 | 2017 | 0.000 |
Why?
|
| Cell Movement | 1 | 1988 | 480 | 0.000 |
Why?
|
| Cell Line | 1 | 1990 | 2071 | 0.000 |
Why?
|
| Neurons | 1 | 1988 | 949 | 0.000 |
Why?
|
| Signal Transduction | 1 | 1990 | 3157 | 0.000 |
Why?
|